Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-617 + Sipuleucel-T in mCRPC
NCT07219147Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Mar 2026
- Primary completion
- Jul 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by City of Hope. Primary endpoints: Anti-prostatic acid phosphatase (PAP) immunoglobulin G (IgG) antibody response rate and Change in anti-PAP IgG antibody titers. Started Mar 2026; status: recruiting.
02
Drugs
sipuleucel-T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07219147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219147.